Corvus Pharmaceuticals, Inc.
CRVSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Corvus Pharmaceuticals, Inc. (CRVS) is listed under Biotechnology. With a market capitalization of $885.8M, it sits in small-cap territory. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Market Cap
$885.8M
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
-9.86
EPS (TTM)
$-0.61
EPS (Fwd)
$-1.07
ROE
-35.4%
ROA
-21.7%
Cash
$215.2M
Total Debt
$728,000
Free CF
-$27.4M
52W Change
43.3%
Annual Financials
Cash vs Debt
Where CRVS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRVS finished 28.99% below its 150-day moving average ($13.59) and 32.47% below its 200-day moving average ($14.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRVS overbought or oversold?
At the October 20, 2026 close, CRVS's RSI(14) was 23.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $215.2M in cash and $728K in debt, CRVS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$27.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -35.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CRVS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Corvus Pharmaceuticals, Inc. and its sector.